BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsEarnings

Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus’ retina pipeline with a Phase 3

Related news

TARSTarsus Pharmaceuticals2026-05-06 20:05 EST

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

TARSTarsus Pharmaceuticals2026-08-06 00:03 EST

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

KPRXKiora Pharmaceuticals2026-08-07 11:00 EST

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

OCGNOcugen2026-08-06 11:02 EST

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

EYPTEyePoint Pharmaceuticals2026-08-05 11:00 EST

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

KPRXKiora Pharmaceuticals2026-05-08 11:00 EST

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

BLTEBelite Bio2026-08-06 12:00 EST

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

TARSTarsus Pharmaceuticals2026-08-06 00:03 EST

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

TARSTarsus Pharmaceuticals2026-07-13 20:05 EST

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Stock data

Close
65.33 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States